>>Description of the research protocol "PREDICTUMAB"

Predictive factors of response to olalizumab and mepolizumab in severe (allergic and eosinophilic) asthma: a multicentre, open, active-controlled, randomized trial in adult patients in Belgium (PREDICTUMAB)
Phase IV study| Status : Ongoing and recruiting

Additional details

Indication (or studied pathology) : Immuno-allergologie
Brugmann identifier : PREDICTUMAB
EudraCT identifier : 2017-002473-19
ClinicalTrials.gov identifier : NCT03476109


Involved department : Immuno-allergology
Principal investigator : Michel
Sponsor : UCL
Contact : Clinical Research Unit

>This protocol was approved by the UCL St Luc ethics committee.